Questioning the FDA's authority to issue a rule that would ultimately put generic drugmakers on the legal hook for "failure-to-warn" claims, several brand and generic companies urged the agency Friday to consider their alternative, which would make the FDA responsible for drug labeling changes once there's generic competition.